Novartis/Amgen migraine drug hits late-stage goals

An experimental therapy being developed by Amgen and Novartis to prevent chronic migraine has hit its primary targets in a late-stage trial, further raising hopes for a new treatment option for the co…
Read the full story: PharmaTimes: News RSS